Mcl-1, Bcl-XL and Stat3 expression are associated with progression of melanoma whereas Bcl-2, AP-2 and MITF levels decrease during progression of melanoma
Open accessThe DOI matches its Crossref record; 57 of the 58 references it cites were found in a registry or an index.
Abstract
Members of the Bcl-2 family of antiapoptotic proteins (Bcl-2, Bcl-XL and Mcl-1) are key regulators of apoptosis. The purpose of the present study was to examine and better define the role of Bcl-2, Bcl-XL and Mcl-1 in the progression of melanoma. Immunohistochemical staining for Bcl-2, Bcl-XL and Mcl-1 was performed on paraffin sections of 100 cases of benign nevi, primary melanoma and metastatic melanoma. Expression was correlated with histopathologic features, clinical progress and expression of transcription factors (AP-2, MITF and p-Stat3). Bcl-2 was expressed in 100% of benign nevi and thin melanoma (<or=1.0 mm) but was less in thick melanoma (>1.0 mm) (88%), subcutaneous (62%) and lymph node metastases (35%). In contrast, Bcl-XL and Mcl-1 were expressed at lower levels in nevi and thin melanoma compared to Bcl-2 but their expression was much higher in thick melanoma and in subcutaneous and lymph node metastases (P<0.0001). Bcl-2 expression was negatively associated with tumor thickness (P<0.05) but Bcl-XL expression increased with increasing tumor thickness (P<0.05) and dermal tumor mitotic rate (P<0.05). Similarly Mcl-1 expression increased with increasing tumor thickness (P<0.09) and dermal tumor mitotic rate (P<0.17). Bcl-2 expression was positively correlated with expression of the transcription factors microphthalmia transcription factor (MITF) and nuclear AP-2 whereas Bcl-XL (and Mcl-1) expression were positively correlated with p-Stat3. This study is the first to show a clear dissociation between changes in Bcl-2 expression (downregulation) and Bcl-XL, Mcl-1 expression (upregulation) during progression of melanoma. The results were also consistent with a role for AP-2 and MITF in regulation of Bcl-2 and pStat3 in regulation of Bcl-XL. These findings have important implications for the development of treatments targeting antiapoptotic proteins in patients with melanoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Constitutive STAT3 activation leads to evasion of apoptosis and a subsequent increase in cell survival.”
From Critical analysis of the potential for targeting STAT3 in human malignancy (2013) · cites this paper as [77]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“STAT3-mediated upregulation of Bcl-xL, Bcl-2, and Mcl-1 contributes to apoptosis evasion in several cancers.77–79”
From Critical analysis of the potential for targeting STAT3 in human malignancy (2013) · cites this paper as [77]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“STAT3 transcriptionally regulates several Bcl-2 family members, including the antiapoptotic proteins Bcl-xL, Bcl-2, and Mcl-1.77”
From Critical analysis of the potential for targeting STAT3 in human malignancy (2013) · cites this paper as [77]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Expression of MITF, which correlates with increased lysosomal gene expression in melanoma cells100, decreases with disease progression97,101.”
From Mechanisms and prevention of UV‐induced melanoma (2018) · cites this paper as [97]
In the citing paper
“Furthermore, BH3-family proteins Bcl-XL and MCL-1, which disrupt the activation of autophagy by Beclin1, are upregulated in metastatic melanomas97.”
From Mechanisms and prevention of UV‐induced melanoma (2018) · cites this paper as [97]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Bcl2 family: regulators of the cellular life-or-death switch
Cory, S., & Adams, J. M. (2002) · Nature Reviews Cancer · doi:10.1038/nrc883 · Cited by 4,032 · cited 1×
“Members of the Bcl-2 (B-cell lymphoma 2) family of proteins are key regulators of apoptosis”
BackgroundProapoptotic BAX and BAK: A Requisite Gateway to Mitochondrial Dysfunction and Death
Wei, M. C., Zong, W.-X., Cheng, E. H.-Y., Lindsten, T., Panoutsakopoulou, V., Ross, A. J., Roth, K. A., MacGregor, G. R., Thompson, C. B., & Korsmeyer, S. J. (2001) · Science · doi:10.1126/science.1059108 · Cited by 3,988
bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death
Boise, L. H., González-García, M., Postema, C. E., Ding, L., Lindsten, T., Turka, L. A., Mao, X., Nuñez, G., & Thompson, C. B. (1993) · Cell · doi:10.1016/0092-8674(93)90508-n · Cited by 3,087 · cited 1×
“The protein product of the longer Bcl-X mRNA (Bcl-XL) becomes as a repressor of apoptosis”
BackgroundChen, L., Willis, S. N., Wei, A., Smith, B. J., Fletcher, J. I., Hinds, M. G., Colman, P. M., Day, C. L., Adams, J. M., & Huang, D. C. S. (2005) · Molecular Cell · doi:10.1016/j.molcel.2004.12.030 · Cited by 1,816
Involvement of the bcl -2 Gene in Human Follicular Lymphoma
Tsujimoto, Y., Cossman, J., Jaffe, E., & Croce, C. M. (1985) · Science · doi:10.1126/science.3874430 · Cited by 1,786
Cheng, E. H.-Y. A., Wei, M. C., Weiler, S., Flavell, R. A., Mak, T. W., Lindsten, T., & Korsmeyer, S. J. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00320-3 · Cited by 1,707 · cited 1×
“Bcl-2 associated X protein (Bax) and Bak are additional proapoptotic proteins that appear to be essential for induction of apoptosis”
BackgroundLetai, A., Bassik, M. C., Walensky, L. D., Sorcinelli, M. D., Weiler, S., & Korsmeyer, S. J. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00127-7 · Cited by 1,677 · cited 1×
“3 The precise interactions between the Bcl-2 proteins leading to apoptosis remain uncertain but two BH3 proteins, Bid and Bim, appear to directly activate Bax and Bak and bind to mitochondria”
BackgroundWillis, S. N., Chen, L., Dewson, G., Wei, A., Naik, E., Fletcher, J. I., Adams, J. M., & Huang, D. C. S. (2005) · Genes & Development · doi:10.1101/gad.1304105 · Cited by 1,233 · cited 1×
“Recent studies have also suggested that there may be some selectivity of the proapoptotic BH3 only proteins for particular antiapoptotic proteins for example Noxa appears to bind to Mcl-1 and Bcl-XL but not Bcl-2”
BackgroundMCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2.
Kozopas, K. M., Yang, T., Buchan, H. L., Zhou, P., & Craig, R. W. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3516 · Cited by 961 · cited 1×
“7 Mcl-1 was first reported in differentiating myeloid cells”
BackgroundZhong, Q., Gao, W., Du, F., & Wang, X. (2005) · Cell · doi:10.1016/j.cell.2005.06.009 · Cited by 842 · cited 1×
“49 perhaps by the specific Mcl-1 ubiquitin ligase E3 (Mule)”
BackgroundMcGill, G. G., Horstmann, M., Widlund, H. R., Du, J., Motyckova, G., Nishimura, E. K., Lin, Y.-L., Ramaswamy, S., Avery, W., Ding, H.-F., et al. (2002) · Cell · doi:10.1016/s0092-8674(02)00762-6 · Cited by 760 · cited 1×
“One of these is the microphthalmia associated transcription factor (MITF) that is believed to be responsible for differentiation and survival of melanocyte”
BackgroundMechanisms of hair graying: incomplete melanocyte stem cell maintenance in the niche
Nishimura, E. K., Granter, S. R., & Fisher, D. E. (2005) · Science · doi:10.1126/science.1099593 · Cited by 750 · cited 1×
“23 Bcl-2 expression in melanocytes has been reported to protect melanocyte stem cells from apoptosis, as shown by loss of pigmentation in Bcl-2 knockout mice and graying of hair in mice”
BackgroundBedikian, A. Y., Millward, M., Pehamberger, H., Conry, R., Gore, M., Trefzer, U., Pavlick, A. C., DeConti, R., Hersh, E. M., Hersey, P., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.0483 · Cited by 600
Self-citationRoles of activated Src and Stat3 signaling in melanoma tumor cell growth
Niu, G., Bowman, T., Huang, M., Shivers, S., Reintgen, D., Daud, A., Chang, A., Kraker, A., Jove, R., & Yu, H. (2002) · Oncogene · doi:10.1038/sj.onc.1205859 · Cited by 432 · cited 1×
“46 Activation of Stat3 by Src kinases in melanoma cells resulted in upregulation of both Mcl-1 and Bcl-X”
BackgroundImmunohistochemical analysis of in vivo patterns of Bcl-X expression.
Krajewski, S., Krajewska, M., Shabaik, A. S., Wang, H., Irie, S., Fong, L. E., & Reed, J. C. (1994) · PubMed · Cited by 418
Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival
Wuillème-Toumi, S., Robillard, N., Gomez, P., Moreau, P., Le Gouill, S., Avet-Loiseau, H., Harousseau, J.-L., Amiot, M., & Bataille, R. (2005) · Leukemia · doi:10.1038/sj.leu.2403784 · Cited by 335
Targeting Stat3 in cancer therapy
Jing, N., & Tweardy, D. J. (2005) · Anti-Cancer Drugs · doi:10.1097/00001813-200507000-00002 · Cited by 278 · cited 1×
“47 and Stat3 was regarded as a critical transcriptional activator of Mcl-1, Bcl-XL and survivin”
BackgroundYu, C., Bruzek, L. M., Meng, X. W., Gores, G. J., Carter, C. A., Kaufmann, S. H., & Adjei, A. A. (2005) · Oncogene · doi:10.1038/sj.onc.1208841 · Cited by 277
Degenerative Disorders Caused by Bcl-2 Deficiency Prevented by Loss of Its BH3-Only Antagonist Bim
Bouillet, P., Cory, S., Zhang, L.-C., Strasser, A., & Adams, J. M. (2001) · Developmental Cell · doi:10.1016/s1534-5807(01)00083-1 · Cited by 274
Bcl-xL is expressed in neuroblastoma cells and modulates chemotherapy-induced apoptosis.
Dole, M. G., Jasty, R., Cooper, M. J., Thompson, C. B., Núñez, G., & Castle, V. P. (1995) · PubMed · Cited by 235
Song, L., Coppola, D., Livingston, S., Cress, W. D., & Haura, E. B. (2005) · Cancer Biology & Therapy · doi:10.4161/cbt.4.3.1496 · Cited by 215
Olopade, O. I., Adeyanju, M., Safa, A. R., Hagos, F., Mick, R., Thompson, C. B., & Recant, W. M. (1997) · PubMed · Cited by 203
Genomic organization, promoter region analysis, and chromosome localization of the mouse bcl-x gene
Grillot, D. A., González-García, M., Ekhterae, D., Duan, L., Inohara, N., Ohta, S., Seldin, M. F., & Nuñez, G. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.158.10.4750 · Cited by 186
Role of nuclear factor-κ B in melanoma
Amiri, K. I., & Richmond, A. (2005) · Cancer and Metastasis Reviews · doi:10.1007/s10555-005-1579-7 · Cited by 180
Bcl-xL in prostate cancer cells: effects of overexpression and down-regulation on chemosensitivity.
Lebedeva, I. V., Rando, R. F., Ojwang, J. O., Cossum, P. A., & Stein, C. A. (2000) · PubMed · Cited by 171
The role of cell cycle regulatory proteins in the pathogenesis of melanoma
Li, W., Sanki, A., Karim, R. Z., Thompson, J. F., Lee, C. S., Zhuang, L., McCarthy, S. W., & Scolyer, R. A. (2006) · Pathology · doi:10.1080/00313020600817951 · Cited by 158
Self-citationExpression of apoptosis regulators in cutaneous malignant melanoma.
Tang, L., Tron, V. A., Reed, J. C., Mah, K., Krajewska, M., Li, G., Xin Min, Z. H. O. U., Ho, V. C., & Trotter, M. J. (1998) · PubMed · Cited by 152
Antiapoptotic bcl-2 and bcl-xL in advanced malignant melanoma
Leiter, U., Schmid, R. M., Kaskel, P., Peter, R. U., & Krähn, G. M. (2000) · Archives of Dermatological Research · doi:10.1007/s004030050479 · Cited by 144 · cited 1×
“18 The role of these proteins in the progression of melanoma is uncertain”
BackgroundMcl-1 Antisense Therapy Chemosensitizes Human Melanoma in a SCID Mouse Xenotransplantation Model
Thallinger, C., Wolschek, M. F., Wacheck, V., Maierhofer, H., Günsberg, P., Polterauer, P., Pehamberger, H., Monia, B. P., Selzer, E., Wolff, K. S., et al. (2003) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.2003.12252.x · Cited by 111
Karjalainen, J. M., Kellokoski, J. K., Eskelinen, M. J., ALHAVA, E. M., & Kosma, V. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.11.3584 · Cited by 108
bcl-2 Protein Expression in Cutaneous Malignant Melanoma and Benign Melanocytic Nevi
Cerroni, L., Soyer, H. P., & Kerl, H. (1995) · The American Journal of Dermatopathology · doi:10.1097/00000372-199502000-00002 · Cited by 102
Induction of apoptosis in lung-cancer cells followingbcl-xL anti-sense treatment
Leech, S. H., Olie, R. A., Gautschi, O. P., Sim�es-W�st, A. P., Tschopp, S., H�ner, R., Hall, J., Stahel, R. A., & Zangemeister‐Wittke, U. (2000) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(20000515)86:4<570::aid-ijc20>3.0.co;2-t · Cited by 96
Heere‐Ress, E., Thallinger, C., Lucas, T., Schlagbauer‐Wadl, H., Wacheck, V., Monia, B. P., Wolff, K. S., Pehamberger, H., & Jansen, B. (2002) · International Journal of Cancer · doi:10.1002/ijc.10248 · Cited by 85
Bcl-xLIs Expressed in Ovarian Carcinoma and Modulates Chemotherapy-Induced Apoptosis
Liu, J. R., Fletcher, B., Page, C., Hu, C., Núñez, G., & Baker, V. V. (1998) · Gynecologic Oncology · doi:10.1006/gyno.1998.5125 · Cited by 85
Olie, R. A., Hafner, C., Küttel, R., Sigrist, B., Stahel, R. A., Zangemeister‐Wittke, U., Willers, J., Dummer, R., & Hall, J. (2002) · Journal of Investigative Dermatology · doi:10.1046/j.0022-202x.2001.01677.x · Cited by 83
Horinaga, M., Okita, H., Nakashima, J., Kanao, K., Sakamoto, M., & Murai, M. (2005) · Urology · doi:10.1016/j.urology.2005.03.066 · Cited by 79
Immunohistochemical analysis of Bcl-2 protein regulation in cutaneous melanoma.
Tron, V. A., Krajewski, S., Klein-Parker, H., Li, G., Ho, V. C., & Reed, J. C. (1995) · PubMed Central · Cited by 78
DiVito, K. A., Berger, A. J., Camp, R. L., Dolled-Filhart, M. P., Rimm, D. L., & Kluger, H. M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1387 · Cited by 77 · cited 1×
“Instead, our results show that Bcl-2 expression was associated with a good prognosis, as reported by Divito et al”
ResultImmunohistochemical expression of BCL‐2 in melanomas and intradermal nevi
Saenz-Santamaria, M. C., Reed, J. A., McNutt, N. S., & Shea, C. R. (1994) · Journal of Cutaneous Pathology · doi:10.1111/j.1600-0560.1994.tb00278.x · Cited by 67 · cited 1×
“Similar results were reported by Saenz-Santamaria et al”
ResultBerger, A. J., Davis, D. W., Tellez, C. S., Prieto, V. G., Gershenwald, J. E., Johnson, M. M., Rimm, D. L., & Bar‐Eli, M. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2300 · Cited by 66 · cited 1×
“39 Reports by others have suggested that translocation of AP-2 from the cytoplasm to the nucleus is disrupted during melanoma progression and is a crucial event in the development of melanoma”
BackgroundRegulation of gene expression in melanoma: New approaches for treatment
Leslie, M. C., & Bar‐Eli, M. (2004) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20296 · Cited by 65 · cited 1×
“Another transcription factor regulating Bcl-2 (and C-kit) is AP-2”
Backgroundbcl-xl antisense treatment induces apoptosis in breast carcinoma cells
Simões‐Wüst, A. P., Olie, R. A., Gautschi, O. P., Leech, S. H., Häner, R., Hall, J., Fabbro, D., Stahel, R. A., & Zangemeister‐Wittke, U. (2000) · International Journal of Cancer · doi:10.1002/1097-0215(20000815)87:4<582::aid-ijc19>3.0.co;2-p · Cited by 64
bcl-2 protein expression in melanocytic neoplasms of the skin.
Ramsay, J. A., From, L., & Kahn, H. J. (1995) · PubMed · Cited by 63
Antigen Retrieval Techniques: Immunohistochemistry and Molecular Morphology
Shi, S., Gu, J., & Taylor, C. R. (2000) · Medical Entomology and Zoology · Cited by 56
Negative regulation of Fas-mediated apoptosis by FAP-1 in human cancer cells
Li, Y., Kanki, H., Hachiya, T., Ohyama, T., Irie, S., Tang, G.-L., Mukai, J., & Sato, T.-A. (2000) · International Journal of Cancer · doi:10.1002/1097-0215(20000815)87:4<473::aid-ijc3>3.0.co;2-1 · Cited by 52
Selzer, E., Thallinger, C., Höeller, C., Oberkleiner, P., Wacheck, V., Pehamberger, H., & Jansen, B. (2002) · Molecular Medicine · doi:10.1007/bf03402094 · Cited by 50
Effects of Bcl-2 and Bcl-XL protein levels on chemoresistance of hepatoblastoma HepG2 cell line
Luo, D., Cheng, S. C.-S., Xie, H. J., & Xie, Y. (2000) · Biochemistry and Cell Biology · doi:10.1139/bcb-78-2-119 · Cited by 45
Jankú, F., Novotný, J. P., Julis, I., Julišová, I., Pecen, L., Tomancová, V., Kocmanova, G., Krásná, L., Krajsová, I., Štork, J., et al. (2005) · Melanoma Research · doi:10.1097/00008390-200508000-00004 · Cited by 40 · cited 1×
“MITF is regulated through C-kit and C-kit is downregulated in melanoma cells”
BackgroundExpression of stress protein gp96, a tumor rejection antigen, in human colorectal cancer
Heike, M., Frenzel, C., Meier, D., & Galle, P. R. (2000) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(20000515)86:4<489::aid-ijc7>3.0.co;2-d · Cited by 27
Collins, K. A., & White, W. L. (1995) · American Journal of Dermatopathology · doi:10.1097/00000372-199510000-00001 · Cited by 26
Antigen Retrieval Techniques: Immunohistochemistry and Molecular Morphology
LiVolsi, V. A. (2001) · Human Pathology · doi:10.1016/s0046-8177(01)70028-7 · Cited by 25
Expression and prognostic relevance of Mcl-1 in breast cancer.
O’Driscoll, L., Cronin, D., Kennedy, S., Purcell, R. V., Linehan, R., Glynn, S. A., Larkin, A., Scanlon, K., McDermott, E. W. M., Hill, A., et al. (2004) · PubMed · Cited by 22
Overexpression of anti‐apoptotic Mcl‐1 in testicular germ cell tumours
Sano, M., Nakanishi, Y., Yagasaki, H., Honma, T., Oinuma, T., Obana, Y., Suzuki, A., & Nemoto, N. (2005) · Histopathology · doi:10.1111/j.1365-2559.2005.02118.x · Cited by 18
Effects of Bcl-2 and Bcl-XL protein levels on chemoresistance of hepatoblastoma HepG2 cell line
Luo, D., Cheng, S. C.-S., Xie, H. J., & Xie, Y. (2000) · Biochemistry and Cell Biology · doi:10.1139/o00-008 · Cited by 16
Regulation of Lymphoid Apoptosis by Bcl-2 and Bcl-xL
Núñez, G., Merino, R., Simonian, P. L., & Grillot, D. (1996) · Advances in experimental medicine and biology · doi:10.1007/978-1-4899-0274-0_8 · Cited by 15
Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma
Millward, M. J. (2006) · UWA Profiles and Research Repository (UWA) · Cited by 10
Cited by
Role of interleukin-6 in cancer progression and therapeutic resistance
Kumari, N., Dwarakanath, B. S., Das, A., & Bhatt, A. N. (2016) · Tumor Biology · doi:10.1007/s13277-016-5098-7 · Cited by 1,092
“Besides evading growth suppression signalling, by loss of TP53 function, tumours are also associated with an increase in the expression of anti-apoptotic regulators (Bcl-2, Bcl-xL and Mcl-1) and survival signals (Igf1/2) or downregulated pro-apoptotic factors (Bax, Bim and Puma) [96, 97].”
BackgroundSTAT3 as a target for inducing apoptosis in solid and hematological tumors
Al Zaid Siddiquee, K., & Turkson, J. (2008) · Cell Research · doi:10.1038/cr.2008.18 · Cited by 487
Perciavalle, R. M., Stewart, D. P., Koss, B., Lynch, J., Milasta, S., Bathina, M., Temirov, J., Cleland, M. M., Pelletier, S., Schuetz, J. D., et al. (2012) · Nature Cell Biology · doi:10.1038/ncb2488 · Cited by 410
Mechanisms and prevention of UV‐induced melanoma
Sample, A., & He, Y. (2018) · Photodermatology, Photoimmunology & Photomedicine · doi:10.1111/phpp.12329 · Cited by 372
Mcl-1 is a potential therapeutic target in multiple types of cancer
Akgul, C. (2009) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-8637-6 · Cited by 329
Metadata
- Authors
- Zhuang, L., Lee, C. S., Scolyer, R. A., McCarthy, S. W., Zhang, X. D., Thompson, J. F., & Hersey, P.
- Affiliations
- The University of Sydney (AU)
- Royal Prince Alfred Hospital (AU)
- Corresponding author
- Hersey, Peter
- Venue
- Modern Pathology
- Publisher
- Elsevier BV
- Published
- 2007-04
- Volume
- 20
- Issue
- 4
- Pages
- 416-426
- ISSN
- 0893-3952 (ISSN-L)
- OpenAlex
- W2086851270
- Cited by
- 202
- References
- 58
- Citations by year
- 2026: 4 · 2025: 4 · 2024: 4 · 2023: 5 · 2022: 3 · 2021: 6 · 2020: 7 · 2019: 9 · 2018: 7 · 2017: 13 · 2016: 17 · 2015: 10 · 2014: 11 · 2013: 17 · 2012: 8
- FWCI
- 8.91
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 5764 d)
- Locations
- Modern Pathology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Cancer Research Institute
- Medical Research Council
- National Health and Medical Research Council
- National Medical Research Council
- Topics
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- melanoma progression, Bcl-2, Bcl-xL, Mcl-1, anti-apoptotic proteins, apoptosis, STAT3 phosphorylation, MITF, AP2 transcription factor, tumor thickness, metastasis, benign nevi
- MeSH terms
- Adolescent, Adult, Aged, Aged, 80 and over, Female, Humans, Lymph Nodes, Lymphatic Metastasis, Male, Melanoma, Middle Aged, Neoplasm Proteins, Skin Neoplasms, Biomarkers, Tumor, Disease Progression, Fluorescent Antibody Technique, Indirect, Proto-Oncogene Proteins c-bcl-2, Transcription Factor AP-2, STAT3 Transcription Factor, bcl-X Protein, Microphthalmia-Associated Transcription Factor, Myeloid Cell Leukemia Sequence 1 Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.